Increasing Prevalence of Metabolic Disorders to Drive the Asia-Pacific Metabolic Disorder Therapeutics Market

Asia-Pacific metabolic disorder therapeutics market is estimated to grow at a CAGR of 8.2% during the forecast period. Obesity and Diabetes is a major health concern in the countries including China and India. As per the World Health Organization (WHO), obesity rates in younger children in China (ages 5-19) was 17.5% in 2016. 1 in 5 Chinese children is obese or overweight, increased from just 1 in 20 in 1995. Further, as per the World Bank, in China, the prevalence of diabetes among the population ages 20-79 was 9.2% in 2019. This results in an increasing demand for insulin-sensitizing drugs, including thiazolidinediones and metformin, for the treatment of any type 2 diabetic patient. 

Browse the full report description Asia-Pacific Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others), and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/asia-pacific-metabolic-disorder-therapeutics-market

These drugs can also be used in patients suffering from metabolic syndrome. At the starting of the therapy, metformin is normally used and thereafter insulin sensitizers (PPAR-gamma stimulators) including rosiglitazone are also recommended. PPARgamma (peroxisome- proliferator-activated receptor-gamma) is considered as a crucial therapeutic target to treat diabetes which arises from its effects of hypoglycemic in diabetic patients and also plays a critical role in controlling CVD functions.

Scope of the Asia-Pacific Metabolic Disorder Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Therapy and Disease
• Countries Covered- China, India, Japan, and Rest of Asia-Pacific
• Competitive Landscape- Lupin Ltd., Shanghai Fosun Pharmaceutical Group (Co.) Ltd., AstraZeneca plc, and Cipla Inc.

Recent Strategic Initiatives in the Asia-Pacific Metabolic Disorder Therapeutics Market

• In February 2020, AstraZeneca India declared the launch of Qtern (Dapagliflozin 10mg + Saxagliptin 5mg film Coated Tablets) to treat type 2 diabetes. It is indicated as an adjunct to exercise and diet for improvement of glycemic control in adults with type 2 diabetes mellitus. This oral medication aims to improve blood sugar levels with a significantly low risk of hypoglycemia.
• In November 2019, Lupin declared the launch of the US generic potassium chloride for the oral solution which is intended for the treatment and prevention of hypokalemia. This is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is inadequate. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia-Pacific Metabolic Disorder Therapeutics Market-Segmentation

By Therapy

• Drug Therapy
• Gene Therapy
• Cellular Transplantation
• Enzyme Replacement Therapy
• Others

By Disease

• Obesity
• Diabetes
• Lysosomal Storage Disease
• Hypercholesterolemia
• Others

Asia-Pacific Metabolic Disorder Therapeutics Market– Segment by Country

• China
• Japan
• India
• Rest of Asia-Pacific